Profit Warnings & Insulin Pricing

MarcusWelcome to the Access Brief — your daily briefing on what's moving in HEOR, HTA, and market access. I'm Marcus, and it's great to have you with us today.

SaraAnd I'm Sara. Always good to be here — and I'll say, today's topics hit close to home on both sides of the value equation.

MarcusSame here. We're looking at HCA's profit warning signaling access erosion in US hospitals — that's a real-time pressure point. Then the subcutaneous Leqembi approval and its unchanged price — a classic value-access tension. The FTC settlement with CVS Caremark over insulin pricing — that could redefine PBM transparency. And ICER's expansion of early-phase scientific advice — a potential game-changer for evidence generation.

SaraThat second one about Leqembi really catches my attention — the budget impact question for health systems with high-deductible plans is one we haven't fully quantified yet.

MarcusExactly. Let's get into it.

MarcusKicking off with HCA Healthcare's profit warning. They cited a 15% increase in bad debt due to patients struggling with out-of-pocket costs. This isn't just financial noise — it's a structural signal that high-deductible plans are creating access barriers for innovative therapies.

SaraThat's one read — but what strikes me is how this reflects a systemic shift. When hospital operators flag patient financial responsibility as a risk factor, it means we're past isolated anecdotes. This is about real-world affordability crunching at the system level.

MarcusAbsolutely. And the implications for HEOR are immediate. We need to model how patient cost-sharing affects uptake, especially for high-cost drugs. The bad debt metric should become a standard variable in access forecasting.

SaraI'd push back slightly on that — while uptake modeling is crucial, the bigger issue here is the misalignment between drug pricing and health system economics. HCA's warning shows that even with efficacy, if the financial burden shifts to patients, the entire care delivery model fractures.

MarcusThat's fair, though I think payers would see this as a coverage design problem. The solution isn't just lower prices — it's smarter benefit structures that protect both innovation and sustainability.

SaraRight, and from the payer side, this is where we start asking about value-based contracting tied to patient financial burden metrics. HCA's warning gives us leverage to reframe those conversations.

MarcusExactly. And what's interesting is how this connects to the Leqembi approval we'll discuss next — same system, same access pressures.

MarcusSpeaking of which, the FDA's approval of subcutaneous Leqembi. The route change reduces infusion burden, which is clinically meaningful. But the price remains unchanged at $26,500 per year. So we've got a better delivery method without any cost adjustment.

SaraThat's one read — I'd frame it slightly differently. The administration improvement doesn't address the core value proposition question: is this incremental clinical benefit worth the full price tag when we have competing therapies? The payer perspective here is about opportunity cost.

MarcusWhat strikes me is the timing. With HCA's warning fresh, this pricing decision feels tone-deaf. The subcutaneous formulation should have been paired with value evidence — maybe a risk-sharing agreement or outcomes-based pricing.

SaraThe part that gives me pause is how this sets a precedent. If we accept unchanged pricing for delivery improvements, what does that mean for future value-based assessments? We risk conflating convenience with innovation.

MarcusThat's fair, though I think manufacturers would argue that the evidence package already justifies the price. The real question is whether payers will differentiate between IV and SC formulations in their coverage decisions.

SaraAnd that's where budget impact simulations become critical. We need to model how SC uptake affects total system costs versus the IV version. HCA's warning suggests those models will show increased financial risk.

MarcusExactly. This is one of those stories where the clinical advance outpaces the value conversation. We'll be watching how health systems respond to that gap.

MarcusShifting to the FTC settlement with CVS Caremark. $15 million penalty and a $35/month insulin cap. This isn't just about insulin — it's about PBM transparency and how rebates get passed through to patients.

SaraI wonder if that's the full picture though. While the $35 cap is significant, the real precedent is the requirement for PBM pricing model reforms. That could reshape how we negotiate rebates across all high-cost drugs, not just insulin.

MarcusWhat's striking here is the enforcement mechanism. The FTC isn't just penalizing past behavior — they're mandating future transparency. That forces PBMs to justify their pricing decisions in ways they haven't before.

SaraThat connects to something I keep coming back to: the hidden costs of pharmacy benefit design. This settlement pulls back the curtain on how rebate structures create affordability gaps for patients. For HEOR, it means we need to model net prices more accurately in value assessments.

MarcusAbsolutely. And from the innovation side, this could actually help manufacturers by creating more predictable patient access. If insulin becomes consistently affordable, that frees up budget for novel therapies.

SaraRight, and from the payer side, the opportunity cost argument gets stronger. When insulin prices are controlled, we can reallocate resources toward higher-value interventions. This settlement might actually accelerate evidence-based coverage decisions.

MarcusExactly. We'll be watching how other PBMs respond to this precedent. Could this be the start of a broader PBM reform movement?

MarcusFinally, ICER's expansion of early-phase scientific advice to include Phase II/III trials. This is a direct response to industry requests for earlier HTA engagement. The goal is to design trials with endpoints that matter to payers.

SaraThat's interesting timing — especially with HCA's warning and Leqembi's pricing. If we get earlier evidence alignment, we might avoid some of those value-access crises. But I wonder about the practical challenges: will HTA bodies have the capacity to engage at Phase II?

MarcusWhat strikes me is how this shifts the evidence generation timeline. Instead of waiting for pivotal data, sponsors can now incorporate payer perspectives during development. That could reduce the evidence gaps that cause access delays.

SaraThe part that gives me pause is methodology. How do we ensure that early-phase advice doesn't become prescriptive? We want flexible trial designs, not rigid HTA constraints that stifle innovation.

MarcusThat's fair, though I think the industry benefits more than it loses. Getting payer input early prevents late-stage surprises. Look at how many drugs fail at HTA due to endpoint mismatches — this could prevent that.

SaraAnd from the payer side, it's about efficiency. If we can influence trial design, we get evidence that's actually useful for coverage decisions. That reduces the need for post-marketing studies, which everyone agrees are inefficient.

MarcusExactly. This might be one of those rare win-win scenarios. We'll be watching how uptake develops and whether it actually reduces submission rejections.

SaraA lot to think about today. I'll be watching how HCA's profit warning influences PBM negotiations on high-cost drugs. The patient financial burden conversation is shifting from anecdote to data.

MarcusSame — and for me the thread running through today is the growing misalignment between innovation delivery and system economics. Whether it's drug pricing, PBM practices, or evidence timing, we're seeing structural pressures that demand new solutions.

SaraThanks so much for listening — really glad you're here with us.

MarcusWe'll be back tomorrow. Show notes and transcripts at outcomes-analytica.no. See you then.

SaraThanks for listening — see you tomorrow.

MarcusBack tomorrow on Access Brief. Show notes at outcomes-analytica.no.